CORNEAL ENDOTHELIUM ECM THERAPEUTIC DRUG - KYOTO PREFECTURAL PUBLIC UNIV CORP

Title:

CORNEAL ENDOTHELIUM ECM THERAPEUTIC DRUG

Document Type and Number:

Japanese Patent JP2023139279

Kind Code:

A

Abstract:

To provide a treatment or preventive drug for diseases, disorders or conditions relating to abnormalities in the extracellular matrix (ECM) of the corneal endothelium, the drug containing a TGF β-signal inhibitor.SOLUTION: More particularly, the diseases, disorders and conditions are disorders related to Fuchs' corneal endothelial dystrophy. Such disorders include photophobia, blurred vision, vision disorders, eye pain, tearing, hyperaemia, pain, bullous keratopathy, eye discomfort, contrast reduction, glare, edema of the corneal stroma, bullous keratopathy and corneal opacity. Preferable TGF β-signal inhibitors include 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.SELECTED DRAWING: None

More Like This:

JP2012512857	Compositions for use on skin and wounds
JP2002526090	INDUSTRIAL APPLICABILITY The polymorphism in the human beta1 integrin subunit gene suitable for the diagnosis and treatment of integrin ligand-mediated diseases.
JP2008054681	PRESSURE-MEDIATED INTRACELLULAR DELIVERY OF MOLECULE OR MICROPARTICLE

Inventors:

KOIZUMI NORIKO
OKUMURA NAOKI
KINOSHITA SHIGERU

Application Number:

JP2023125871A

Publication Date:

October 03, 2023

Filing Date:

August 01, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

KYOTO PREFECTURAL PUBLIC UNIV CORP
DOSHISHA
SENJU PHARMA CO

International Classes:

A61K45/00; A61K31/437; A61K31/4375; A61K31/4402; A61K31/4427; A61K31/4439; A61K31/4709; A61K31/4725; A61K31/4745; A61K31/496; A61K31/519; A61K31/7088; A61K31/713; A61K38/17; A61K39/395; A61K48/00; A61P27/02; A61P43/00

Attorney, Agent or Firm:

Mitsuyoshi Kamada
Hajime Takashima

Previous Patent: vehicle seat

Next Patent: gaming machine